S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   204.05 (-2.02%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   204.05 (-2.02%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   204.05 (-2.02%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   3,333.69 (-0.80%)
DOW   27,686.91 (-0.38%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   204.05 (-2.02%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:SUPNSupernus Pharmaceuticals Stock Price, Forecast & News

$22.81
-0.22 (-0.96 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$22.47
Now: $22.81
$24.15
50-Day Range
$22.26
MA: $23.52
$24.94
52-Week Range
$13.12
Now: $22.81
$29.81
Volume1.13 million shs
Average Volume559,509 shs
Market Capitalization$1.20 billion
P/E Ratio10.51
Dividend YieldN/A
Beta1.55
Supernus Pharmaceuticals, Inc., a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine. The company's product candidates comprise SPN-812, a viloxazine hydrochloride, which is in Phase III clinical trial that is used for the treatment of attention deficit hyperactivity disorder (ADHD); SPN-810, a molindone hydrochloride that is in Phase III clinical trial for the treatment of impulsive aggression in patients with ADHD; SPN-809, a viloxazine hydrochloride, which is in Phase II ready clinical trial for the treatment of depression; SPN-604 extended release oxcarbazepine for bipolar; and SPN-817 that is in phase I clinical trial for treating epilepsy. The company markets its products through wholesalers and distributors. Supernus Pharmaceuticals, Inc. was founded in 2005 and is based in Rockville, Maryland.
Read More
Supernus Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.1Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 2.5 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.73 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:SUPN
CUSIP86845910
Phone301-838-2500

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$392.76 million
Cash Flow$2.47 per share
Book Value$11.35 per share

Profitability

Net Income$113.06 million

Miscellaneous

Employees448
Market Cap$1.20 billion
Next Earnings Date8/11/2020 (Estimated)
OptionableOptionable
$22.81
-0.22 (-0.96 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SUPN News and Ratings via Email

Sign-up to receive the latest news and ratings for SUPN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions

How has Supernus Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Supernus Pharmaceuticals' stock was trading at $16.15 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SUPN stock has increased by 41.2% and is now trading at $22.81.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Supernus Pharmaceuticals?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 3 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Supernus Pharmaceuticals
.

When is Supernus Pharmaceuticals' next earnings date?

Supernus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 11th 2020.
View our earnings forecast for Supernus Pharmaceuticals
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) released its earnings results on Tuesday, May, 5th. The specialty pharmaceutical company reported $0.40 EPS for the quarter, beating analysts' consensus estimates of $0.30 by $0.10. The specialty pharmaceutical company earned $94.98 million during the quarter, compared to analyst estimates of $84.01 million. Supernus Pharmaceuticals had a return on equity of 20.31% and a net margin of 28.90%. The firm's quarterly revenue was up 11.1% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.34 earnings per share.
View Supernus Pharmaceuticals' earnings history
.

What price target have analysts set for SUPN?

4 equities research analysts have issued 1-year target prices for Supernus Pharmaceuticals' shares. Their forecasts range from $24.00 to $31.00. On average, they expect Supernus Pharmaceuticals' stock price to reach $26.33 in the next year. This suggests a possible upside of 15.4% from the stock's current price.
View analysts' price targets for Supernus Pharmaceuticals
.

Has Supernus Pharmaceuticals been receiving favorable news coverage?

Media stories about SUPN stock have trended neutral recently, InfoTrie reports. The research group identifies positive and negative news coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Supernus Pharmaceuticals earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave headlines about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next few days.
View the latest news about Supernus Pharmaceuticals
.

Who are some of Supernus Pharmaceuticals' key competitors?

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Alibaba Group (BABA), Gilead Sciences (GILD), GW Pharmaceuticals PLC- (GWPH), Exelixis (EXEL), Netflix (NFLX), Pfizer (PFE), Cara Therapeutics (CARA) and Corcept Therapeutics (CORT).

Who are Supernus Pharmaceuticals' key executives?

Supernus Pharmaceuticals' management team includes the following people:
  • Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 58)
  • Mr. Gregory S. Patrick, Sr. VP & CFO (Age 68)
  • Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 62)
  • Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 67)
  • Dr. Todd Horich M.B.A., Ph.D., VP of Marketing

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include GW&K Investment Management LLC (1.51%), LSV Asset Management (1.33%), Principal Financial Group Inc. (0.75%), Mutual of America Capital Management LLC (0.73%), Scout Investments Inc. (0.44%) and WINTON GROUP Ltd (0.29%). Company insiders that own Supernus Pharmaceuticals stock include Frederick M Hudson, Gregory S Patrick and Jack A Khattar.
View institutional ownership trends for Supernus Pharmaceuticals
.

Which institutional investors are selling Supernus Pharmaceuticals stock?

SUPN stock was sold by a variety of institutional investors in the last quarter, including WINTON GROUP Ltd, Candriam Luxembourg S.C.A., Principal Financial Group Inc., LSV Asset Management, US Bancorp DE, Texas Permanent School Fund, Mackay Shields LLC, and Pacer Advisors Inc.. Company insiders that have sold Supernus Pharmaceuticals company stock in the last year include Frederick M Hudson, and Gregory S Patrick.
View insider buying and selling activity for Supernus Pharmaceuticals
.

Which institutional investors are buying Supernus Pharmaceuticals stock?

SUPN stock was bought by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, First Trust Advisors LP, HighTower Advisors LLC, Mutual of America Capital Management LLC, Smith Asset Management Group LP, SG Americas Securities LLC, Nisa Investment Advisors LLC, and Wakefield Asset Management LLLP.
View insider buying and selling activity for Supernus Pharmaceuticals
.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $22.81.

How big of a company is Supernus Pharmaceuticals?

Supernus Pharmaceuticals has a market capitalization of $1.20 billion and generates $392.76 million in revenue each year. The specialty pharmaceutical company earns $113.06 million in net income (profit) each year or $2.10 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe.

What is Supernus Pharmaceuticals' official website?

The official website for Supernus Pharmaceuticals is www.supernus.com.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.